| Dr Raymond S Michael, MD | |
|
300 South Bruce St, Marshall, MN 56258 | |
| (507) 532-9631 | |
| (507) 532-1176 |
| Full Name | Dr Raymond S Michael |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 46 Years |
| Location | 300 South Bruce St, Marshall, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417923715 | NPI | - | NPPES |
| 388618200 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 46383 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera Marshall Regional Medical Ctr | Marshall, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Avera Marshall | 5799695227 | 75 |
| Rural Health Care Inc | 3476447541 | 130 |
News Archive
Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.
Until now, physicians have largely been skeptical of the advantages of 3D technology. But this may be about to change: the findings of a new study show that even experienced surgeons stand to benefit from the third dimension.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 7 days ago
| Entity Name | Pipestone County Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447300587 PECOS PAC ID: 0840109682 Enrollment ID: O20031105000578 |
News Archive
Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.
Until now, physicians have largely been skeptical of the advantages of 3D technology. But this may be about to change: the findings of a new study show that even experienced surgeons stand to benefit from the third dimension.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 7 days ago
| Entity Name | Avera Marshall |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568401016 PECOS PAC ID: 5799695227 Enrollment ID: O20031106000219 |
News Archive
Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.
Until now, physicians have largely been skeptical of the advantages of 3D technology. But this may be about to change: the findings of a new study show that even experienced surgeons stand to benefit from the third dimension.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 7 days ago
| Entity Name | Pipestone County Medical Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1598751240 PECOS PAC ID: 0840109682 Enrollment ID: O20061121000734 |
News Archive
Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.
Until now, physicians have largely been skeptical of the advantages of 3D technology. But this may be about to change: the findings of a new study show that even experienced surgeons stand to benefit from the third dimension.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 7 days ago
| Entity Name | Avera Marshall |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1568401016 PECOS PAC ID: 5799695227 Enrollment ID: O20091209000435 |
News Archive
Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.
Until now, physicians have largely been skeptical of the advantages of 3D technology. But this may be about to change: the findings of a new study show that even experienced surgeons stand to benefit from the third dimension.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 7 days ago
| Entity Name | Rural Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215317375 PECOS PAC ID: 3476447541 Enrollment ID: O20150710000034 |
News Archive
Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.
Until now, physicians have largely been skeptical of the advantages of 3D technology. But this may be about to change: the findings of a new study show that even experienced surgeons stand to benefit from the third dimension.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Raymond S Michael, MD 300 South Bruce St, Marshall, MN 56258 Ph: (507) 532-9631 | Dr Raymond S Michael, MD 300 South Bruce St, Marshall, MN 56258 Ph: (507) 532-9631 |
News Archive
Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.
Until now, physicians have largely been skeptical of the advantages of 3D technology. But this may be about to change: the findings of a new study show that even experienced surgeons stand to benefit from the third dimension.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 7 days ago
Dr. Heather Elaine Reber, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 S Bruce St, Avera Marshall, Marshall, MN 56258 Phone: 507-537-9007 Fax: 507-537-2730 | |
Dr. Bradley Kevin Bloemker, M.D., PH.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 S Bruce St, Marshall, MN 56258 Phone: 507-537-9007 Fax: 507-537-2730 | |
Dr. Donna Rae Hartfiel, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 300 South Bruce Street, Avera Marshall, Marshall, MN 56258 Phone: 507-537-9007 Fax: 507-537-2730 | |
Dr. Glenn Alan Gaunt, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Park Ave, Marshall, MN 56258 Phone: 719-588-4536 Fax: 507-607-8589 |